Neural degeneration in the retina of the streptozotocin-induced type 1 diabetes model

Yoko Ozawa, Toshihide Kurihara, Mariko Sasaki, Norimitsu Ban, Kenya Yuki, Shunsuke Kubota, Kazuo Tsubota

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Diabetic retinopathy, a vision-threatening disease, has been regarded as a vascular disorder. However, impaired oscillatory potentials (OPs) in the electroretinogram (ERG) and visual dysfunction are recorded before severe vascular lesions appear. Here, we review the molecular mechanisms underlying the retinal neural degeneration observed in the streptozotocin-(STZ-) induced type 1 diabetes model. The renin-angiotensin system (RAS) and reactive oxygen species (ROS) both cause OP impairment and reduced levels of synaptophysin, a synaptic vesicle protein for neurotransmitter release, most likely through excessive protein degradation by the ubiquitin-proteasome system. ROS also decrease brain-derived neurotrophic factor (BDNF) and inner retinal neuronal cells. The influence of both RAS and ROS on synaptophysin suggests that RAS-ROS crosstalk occurs in the diabetic retina. Therefore, suppressors of RAS or ROS, such as angiotensin II type 1 receptor blockers or the antioxidant lutein, respectively, are potential candidates for neuroprotective and preventive therapies to improve the visual prognosis.

Original languageEnglish
Article number108328
JournalExperimental Diabetes Research
Volume2011
DOIs
Publication statusPublished - 2011

Fingerprint

Streptozocin
Type 1 Diabetes Mellitus
Retina
Reactive Oxygen Species
Renin-Angiotensin System
Synaptophysin
Blood Vessels
Angiotensin II Type 1 Receptor Blockers
Lutein
Retinal Degeneration
Synaptic Vesicles
Brain-Derived Neurotrophic Factor
Diabetic Retinopathy
Proteasome Endopeptidase Complex
Ubiquitin
Proteolysis
Neurotransmitter Agents
Antioxidants
Oxygen
Diabetes

ASJC Scopus subject areas

  • Medicine(all)
  • Endocrinology, Diabetes and Metabolism
  • Music

Cite this

Neural degeneration in the retina of the streptozotocin-induced type 1 diabetes model. / Ozawa, Yoko; Kurihara, Toshihide; Sasaki, Mariko; Ban, Norimitsu; Yuki, Kenya; Kubota, Shunsuke; Tsubota, Kazuo.

In: Experimental Diabetes Research, Vol. 2011, 108328, 2011.

Research output: Contribution to journalArticle

@article{1ab0812acd0941ea84c6a413be477ee5,
title = "Neural degeneration in the retina of the streptozotocin-induced type 1 diabetes model",
abstract = "Diabetic retinopathy, a vision-threatening disease, has been regarded as a vascular disorder. However, impaired oscillatory potentials (OPs) in the electroretinogram (ERG) and visual dysfunction are recorded before severe vascular lesions appear. Here, we review the molecular mechanisms underlying the retinal neural degeneration observed in the streptozotocin-(STZ-) induced type 1 diabetes model. The renin-angiotensin system (RAS) and reactive oxygen species (ROS) both cause OP impairment and reduced levels of synaptophysin, a synaptic vesicle protein for neurotransmitter release, most likely through excessive protein degradation by the ubiquitin-proteasome system. ROS also decrease brain-derived neurotrophic factor (BDNF) and inner retinal neuronal cells. The influence of both RAS and ROS on synaptophysin suggests that RAS-ROS crosstalk occurs in the diabetic retina. Therefore, suppressors of RAS or ROS, such as angiotensin II type 1 receptor blockers or the antioxidant lutein, respectively, are potential candidates for neuroprotective and preventive therapies to improve the visual prognosis.",
author = "Yoko Ozawa and Toshihide Kurihara and Mariko Sasaki and Norimitsu Ban and Kenya Yuki and Shunsuke Kubota and Kazuo Tsubota",
year = "2011",
doi = "10.1155/2011/108328",
language = "English",
volume = "2011",
journal = "Experimental Diabesity Research",
issn = "1543-8600",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Neural degeneration in the retina of the streptozotocin-induced type 1 diabetes model

AU - Ozawa, Yoko

AU - Kurihara, Toshihide

AU - Sasaki, Mariko

AU - Ban, Norimitsu

AU - Yuki, Kenya

AU - Kubota, Shunsuke

AU - Tsubota, Kazuo

PY - 2011

Y1 - 2011

N2 - Diabetic retinopathy, a vision-threatening disease, has been regarded as a vascular disorder. However, impaired oscillatory potentials (OPs) in the electroretinogram (ERG) and visual dysfunction are recorded before severe vascular lesions appear. Here, we review the molecular mechanisms underlying the retinal neural degeneration observed in the streptozotocin-(STZ-) induced type 1 diabetes model. The renin-angiotensin system (RAS) and reactive oxygen species (ROS) both cause OP impairment and reduced levels of synaptophysin, a synaptic vesicle protein for neurotransmitter release, most likely through excessive protein degradation by the ubiquitin-proteasome system. ROS also decrease brain-derived neurotrophic factor (BDNF) and inner retinal neuronal cells. The influence of both RAS and ROS on synaptophysin suggests that RAS-ROS crosstalk occurs in the diabetic retina. Therefore, suppressors of RAS or ROS, such as angiotensin II type 1 receptor blockers or the antioxidant lutein, respectively, are potential candidates for neuroprotective and preventive therapies to improve the visual prognosis.

AB - Diabetic retinopathy, a vision-threatening disease, has been regarded as a vascular disorder. However, impaired oscillatory potentials (OPs) in the electroretinogram (ERG) and visual dysfunction are recorded before severe vascular lesions appear. Here, we review the molecular mechanisms underlying the retinal neural degeneration observed in the streptozotocin-(STZ-) induced type 1 diabetes model. The renin-angiotensin system (RAS) and reactive oxygen species (ROS) both cause OP impairment and reduced levels of synaptophysin, a synaptic vesicle protein for neurotransmitter release, most likely through excessive protein degradation by the ubiquitin-proteasome system. ROS also decrease brain-derived neurotrophic factor (BDNF) and inner retinal neuronal cells. The influence of both RAS and ROS on synaptophysin suggests that RAS-ROS crosstalk occurs in the diabetic retina. Therefore, suppressors of RAS or ROS, such as angiotensin II type 1 receptor blockers or the antioxidant lutein, respectively, are potential candidates for neuroprotective and preventive therapies to improve the visual prognosis.

UR - http://www.scopus.com/inward/record.url?scp=84855582942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855582942&partnerID=8YFLogxK

U2 - 10.1155/2011/108328

DO - 10.1155/2011/108328

M3 - Article

C2 - 22144984

AN - SCOPUS:84855582942

VL - 2011

JO - Experimental Diabesity Research

JF - Experimental Diabesity Research

SN - 1543-8600

M1 - 108328

ER -